research Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis
A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.
Search
for
Sort by
Research
270-300 / 1000+ results research Ichthyosis follicularis with alopecia and photophobia in a mother and daughter
A mother and daughter had severe skin, hair, and eye issues linked to IFAP.
research From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata
Alopecia areata is now understood to be driven by genetic and immune factors.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research Alopecia Areata
Alopecia Areata is an autoimmune disease causing hair loss in patches, often starting before age 20, and while some cases recover on their own, treatments include topical corticosteroids, minoxidil, and promising new methods like IL-31 antibodies and 308-nm Excimer laser therapy.
research Alopecia à Deux: Simultaneous Occurrence of Alopecia in a Husband and Wife
A married couple both developed alopecia areata, possibly due to shared stress.
research Immune privilege and alopecia areata
Restoring immune privilege in hair follicles could help treat certain types of hair loss.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
research Alopecia Areata: Update and Current Treatment
Alopecia areata affects about 2% of people and can impact any hair area.
research 282 WITHDRAWN
HIF-1A may aid hair growth, Backhousia citriodora improves skin, autologous cells stabilize hair loss, infrared thermography assesses alopecia, and a new treatment preserves hair.
research Prevalence of alopecia areata in Japan: Estimates from a nationally representative sample
Alopecia areata affects 1.45% of people in Japan, impacting mood and self-esteem, with many not seeking treatment.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research POSTĘP W DIAGNOZIE I LECZENIU STWARDNIENIA ROZSIANEGO
AI and advanced technologies are improving medical diagnostics and treatments.
research Development of Autoimmune Hair Loss Disease Alopecia Areata Is Associated with Cardiac Dysfunction in C3H/HeJ Mice
Mice with autoimmune hair loss showed signs of heart problems.
research Alopecia Areata - Current and Emerging Therapies
New treatments like JAK inhibitors offer hope for hair regrowth in severe alopecia areata.
research ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.
research Interleukin-15 is a hair follicle immune privilege guardian
Interleukin-15 can help hair growth and protect hair follicles.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research The IBHRS Is Up and Running!
The IBHRS is now operational.
research Correlation of carotid intima media thickness and aortic stiffness index with androgenetic alopecia
Men with severe hair loss may have a higher risk of heart disease.
research Atrichia with papular lesions in two Pakistani consanguineous families resulting from mutations in the human hairless gene
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion
HASHA is a safe and effective option for chin augmentation.
research Baricitinib in the Management of Coexisting Alopecia Areata and Atopic Dermatitis: A Case Report
Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.